Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014–2017)

Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014–2017)

Abstract Background Effective treatment options for inoperable, metastatic, or recurrent canine pheochromocytomas are lacking. In humans, specific germline mutations exist that drive the development of pheochromocytomas. Pharmaceutical blockade of these abnormalities with small molecule inhibitors a...

Full description

Bibliographic Details
Main Authors: Margaret L. Musser, Kathryn L. Taikowski, Chad M. Johannes, Philip J. Bergman
Format: Article
Language:English
Published: BMC 2018-09-01
Series:BMC Veterinary Research
Subjects:
Pheochromocytoma
Toceranib
Canine
Metastasis
Recurrent
Online Access:http://link.springer.com/article/10.1186/s12917-018-1597-7

Internet

http://link.springer.com/article/10.1186/s12917-018-1597-7

Similar Items